Correlation Between INmune Bio and X4 Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both INmune Bio and X4 Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining INmune Bio and X4 Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between INmune Bio and X4 Pharmaceuticals, you can compare the effects of market volatilities on INmune Bio and X4 Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in INmune Bio with a short position of X4 Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of INmune Bio and X4 Pharmaceuticals.

Diversification Opportunities for INmune Bio and X4 Pharmaceuticals

0.06

Correlation Coefficient

INmune Bio  X4 Pharmaceuticals

Significant diversification

The 3 months correlation between INmune and XFOR is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding INmune Bio and X4 Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on X4 Pharmaceuticals and INmune Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on INmune Bio are associated (or correlated) with X4 Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of X4 Pharmaceuticals has no effect on the direction of INmune Bio i.e., INmune Bio and X4 Pharmaceuticals go up and down completely randomly.

Pair Corralation between INmune Bio and X4 Pharmaceuticals

Given the investment horizon of 90 days INmune Bio is expected to under-perform the X4 Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, INmune Bio is 3.39 times less risky than X4 Pharmaceuticals. The stock trades about -0.18 of its potential returns per unit of risk. The X4 Pharmaceuticals is currently generating about 0.32 of returns per unit of risk over similar time horizon. If you would invest  37.00  in X4 Pharmaceuticals on October 1, 2024 and sell it today you would earn a total of  43.40  from holding X4 Pharmaceuticals or generate 117.3% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

INmune Bio  vs.  X4 Pharmaceuticals

INmune Bio

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days INmune Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

X4 Pharmaceuticals

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in X4 Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, X4 Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with INmune Bio and X4 Pharmaceuticals

The main advantage of trading using opposite INmune Bio and X4 Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if INmune Bio position performs unexpectedly, X4 Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will offset losses from the drop in X4 Pharmaceuticals' long position.

The idea behind INmune Bio and X4 Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.